What question did this study set out to answer?

The aim is to evaluate the effectiveness of the MTH1 inhibitor TH287 in sensitizing castration-resistant prostate cancer cells to ionizing radiation.

March 16, 2026Open Access

The MTH1 inhibitor TH287 sensitized Castration-Resistant Prostate Cancer cells to ionizing radiation therapy

Key Points

The aim is to evaluate the effectiveness of the MTH1 inhibitor TH287 in sensitizing castration-resistant prostate cancer cells to ionizing radiation.
Administered TH287 to castration-resistant prostate cancer cells.
Applied ionizing radiation therapy 12 hours after TH287 treatment.
Measured tumor cell death rates post-treatment.
TH287 significantly increased tumor cell death when combined with ionizing radiation.
Observations show potent radiosensitization effects of TH287 for CRPC treatment.

Abstract

Overall, TH287 exhibited potent radiosensitization effects for CRPC treatment, effectively killing tumor cells when administered alongside IR at 12 h after the initial drug treatment.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper